WO2004048605A1 - 特定リポ蛋白中の脂質測定法 - Google Patents
特定リポ蛋白中の脂質測定法 Download PDFInfo
- Publication number
- WO2004048605A1 WO2004048605A1 PCT/JP2003/015080 JP0315080W WO2004048605A1 WO 2004048605 A1 WO2004048605 A1 WO 2004048605A1 JP 0315080 W JP0315080 W JP 0315080W WO 2004048605 A1 WO2004048605 A1 WO 2004048605A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- measuring
- cholesterol
- hlb
- ldl
- surfactant
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 96
- 102000004895 Lipoproteins Human genes 0.000 title claims abstract description 76
- 108090001030 Lipoproteins Proteins 0.000 title claims abstract description 76
- 150000002632 lipids Chemical class 0.000 title claims abstract description 76
- 238000005259 measurement Methods 0.000 claims abstract description 65
- 125000003367 polycyclic group Chemical group 0.000 claims abstract description 52
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 134
- 239000003153 chemical reaction reagent Substances 0.000 claims description 85
- 235000012000 cholesterol Nutrition 0.000 claims description 65
- 239000004094 surface-active agent Substances 0.000 claims description 59
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 42
- 230000007935 neutral effect Effects 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 26
- 239000002736 nonionic surfactant Substances 0.000 claims description 24
- 239000000872 buffer Substances 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 15
- 150000003904 phospholipids Chemical class 0.000 claims description 11
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims description 10
- 102000043296 Lipoprotein lipases Human genes 0.000 claims description 9
- 239000007857 degradation product Substances 0.000 claims description 9
- 150000003626 triacylglycerols Chemical class 0.000 claims description 9
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 8
- 108010004103 Chylomicrons Proteins 0.000 claims description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 7
- 239000003945 anionic surfactant Substances 0.000 claims description 5
- 125000005504 styryl group Chemical group 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 1
- 238000000691 measurement method Methods 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 59
- 102000015779 HDL Lipoproteins Human genes 0.000 description 59
- 108010007622 LDL Lipoproteins Proteins 0.000 description 33
- 102000007330 LDL Lipoproteins Human genes 0.000 description 33
- 238000008214 LDL Cholesterol Methods 0.000 description 24
- 239000003925 fat Substances 0.000 description 23
- -1 for example Proteins 0.000 description 21
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 20
- 102000004190 Enzymes Human genes 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 18
- 108010089254 Cholesterol oxidase Proteins 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 102000000019 Sterol Esterase Human genes 0.000 description 13
- 108010055297 Sterol Esterase Proteins 0.000 description 13
- 102000003992 Peroxidases Human genes 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 108040007629 peroxidase activity proteins Proteins 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 10
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 10
- 238000010586 diagram Methods 0.000 description 8
- 108010046315 IDL Lipoproteins Proteins 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- JJYPMNFTHPTTDI-UHFFFAOYSA-N meta-toluidine Natural products CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 6
- 102000004316 Oxidoreductases Human genes 0.000 description 5
- 108090000854 Oxidoreductases Proteins 0.000 description 5
- 108010069201 VLDL Cholesterol Proteins 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 5
- 102000006410 Apoproteins Human genes 0.000 description 4
- 108010083590 Apoproteins Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000005199 ultracentrifugation Methods 0.000 description 4
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 239000007987 MES buffer Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 3
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000003245 coal Substances 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229950006238 nadide Drugs 0.000 description 3
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000004992 toluidines Chemical class 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- UOORRWUZONOOLO-OWOJBTEDSA-N (E)-1,3-dichloropropene Chemical compound ClC\C=C\Cl UOORRWUZONOOLO-OWOJBTEDSA-N 0.000 description 2
- WZSAMJVVWKJQCY-UHFFFAOYSA-N 2-phenyl-2-sulfobutanedioic acid Chemical compound S(=O)(=O)(O)C(C(=O)O)(CC(=O)O)C1=CC=CC=C1 WZSAMJVVWKJQCY-UHFFFAOYSA-N 0.000 description 2
- DQYSALLXMHVJAV-UHFFFAOYSA-M 3-heptyl-2-[(3-heptyl-4-methyl-1,3-thiazol-3-ium-2-yl)methylidene]-4-methyl-1,3-thiazole;iodide Chemical compound [I-].CCCCCCCN1C(C)=CS\C1=C\C1=[N+](CCCCCCC)C(C)=CS1 DQYSALLXMHVJAV-UHFFFAOYSA-M 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000057621 Glycerol kinases Human genes 0.000 description 2
- 108700016170 Glycerol kinases Proteins 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-L NADH(2-) Chemical group C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-L 0.000 description 2
- 239000007990 PIPES buffer Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FAQKWOMUGAZAGU-UHFFFAOYSA-N (2-butyl-3-methylphenyl)-sulfosulfamic acid Chemical compound CCCCC1=C(C)C=CC=C1N(S(O)(=O)=O)S(O)(=O)=O FAQKWOMUGAZAGU-UHFFFAOYSA-N 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- SWPRYOQPODHGMX-UHFFFAOYSA-N 4-(3-methylanilino)butane-1,1-disulfonic acid Chemical compound CC1=CC=CC(NCCCC(S(O)(=O)=O)S(O)(=O)=O)=C1 SWPRYOQPODHGMX-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010000659 Choline oxidase Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 1
- 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
- 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010080123 HDL-triglyceride Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108010008604 L-alpha-glycerol-phosphate oxidase Proteins 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 description 1
- 108020002334 Monoacylglycerol lipase Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010060751 Type III hyperlipidaemia Diseases 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 108010023417 cholesterol dehydrogenase Proteins 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 108010030696 low density lipoprotein triglyceride Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 108010085346 steroid delta-isomerase Proteins 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- JFLKFZNIIQFQBS-FNCQTZNRSA-N trans,trans-1,4-Diphenyl-1,3-butadiene Chemical group C=1C=CC=CC=1\C=C\C=C\C1=CC=CC=C1 JFLKFZNIIQFQBS-FNCQTZNRSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/60—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving cholesterol
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25125—Digestion or removing interfering materials
Definitions
- the present invention relates to a method and a reagent for efficiently separating and quantifying a lipid present in a specific fraction by a simple operation with a small amount of a sample.
- Lipoproteins are classified into chylomicron, ultra-low-density lipoprotein (VLDL, low-density lipoprotein (LDL), and high-density lipoprotein (HDD, etc.) according to differences in physical properties.
- VLDL ultra-low-density lipoprotein
- LDL low-density lipoprotein
- HDD high-density lipoprotein
- IDL and LDL, and lipoprotein degradation products (remnants) may also be treated as one of the lipoproteins Of these lipoproteins, LDL causes atherosclerosis
- HDL is known to exhibit anti-atherosclerotic action.
- apoprotein and cholesterol levels in LDL are positively correlated with the frequency of atherosclerotic disease, while apoprotein and cholesterol levels in HDL are inversely related to the frequency of atherosclerotic disease. It is known that they show a correlation.
- Today, the measurement of apoprotein / cholesterol in LDL and HDL is performed for the purpose of preventing and diagnosing ischemic heart disease.
- LDL or HDL As a method for measuring lipids in LDL or HDL, for example, LDL or HDL is separated from other lipoproteins by ultracentrifugation and then subjected to each lipid measurement, or lipid staining is performed after separation by electrophoresis. A method of measuring the color intensity is known. However, all of these methods have problems such as complicated operations and the inability to process a large number of samples. I got it.
- the most common measurement of lipids in lipoproteins is the measurement of cholesterol in HDL.
- a method used in the field of clinical testing includes adding a precipitant to a sample to aggregate lipoproteins other than HDL, removing the lipoprotein by centrifugation, and removing the separated HD.
- a precipitation method that measures cholesterol in the supernatant containing only L. This method required a relatively large amount of sample, and could not fully automate the entire analysis process.
- methods for enzymatically separating and quantifying HDL cholesterol have been studied.
- a method of performing an enzymatic reaction in the presence of a bile salt and a nonionic surfactant discloses a method of preaggregating lipoproteins other than HDL. After the enzymatic reaction of only cholesterol in HDL, a method of inactivating the enzyme and simultaneously re-dissolving the aggregate to measure the absorbance (Japanese Patent Application Laid-Open No. 6-224110) A method of measuring cholesterol in HDL that does not precipitate by using a combination of a precipitating reagent that precipitates lipoproteins other than HDL and a cholesterol measuring reagent (Japanese Patent Publication No.
- HD L cholesterol is measured next to LDL cholesterol measurement Although the clinical significance was widely known through large-scale epidemiological studies, no method such as the precipitation method for measuring HDL cholesterol was developed.
- the devised conversion formula method (Freidewald method, hereinafter abbreviated as F-expression method) for obtaining the "estimated value" was used.
- LDL cholesterol in the F method is calculated by subtracting HDL cholesterol and VLDL cholesterol from total cholesterol, and a value of 1/5 of the neutral fat concentration is used as VLDL cholesterol.
- VLDL cholesterol is estimated from triglycerides, it cannot be used for people whose triglyceride concentration exceeds 40 Omg / dl or for patients with type III hyperlipidemia, and the diet temporarily increases triglycerides When doing so, there were problems such as negative effects.
- an enzymatic method for LDL cholesterol has also been developed, in which HDL cholesterol is eliminated from a sample containing LDL cholesterol, and the remaining LDL cholesterol is measured (Japanese Patent Application Laid-Open No. 8-828734), a sugar compound and / or a protein.
- There is a method of measuring LDL cholesterol in a sample in the presence of a solubilizing agent Japanese Patent Publication No. 8-829599.
- Method of using a surfactant having a specific structure JP-A-9-313200
- Method of using a surfactant that acts other than LDL in a buffer containing diamine JP-A-10-38888
- the measurement of triglyceride is based on the fact that after free daricerol is consumed in the first reaction, the free glycerol produced by lipoprotein lipase in the second reaction is phosphorylated, and further produced by the action of glycerol phosphate oxidase.
- a method is used in which all of the hydrogen peroxide is reacted with peroxidase, 4-aminoantipyrine and a Trinder dye to form a color.
- a so-called colorless coloring method is used, and peroxidase and one of its substrates, catalase, and combinations thereof are commonly used.
- triglycerides in specific lipoproteins are measured by ultracentrifugation, fractionation using a flocculant, fractionation by gel filtration, etc.
- a surfactant that inhibits the reaction of a lipoprotein other than the specific lipoprotein or a surfactant having an HLB of 15 or more (WO 00/43537). Disclosure of the invention
- an object of the present invention is to provide a method for measuring lipid in a specific fraction, which can be efficiently applied to various automatic analyzers by a simple operation.
- the present inventor conducted intensive research and found that the lipid in the target lipoprotein to be measured in the sample is specifically measured by using a specific surfactant at least in the step of determining the specificity of the target lipid measurement.
- the present invention was completed by finding out what can be done, and that these surfactants have common structural characteristics.
- the present invention provides a method for measuring lipid in a specific lipoprotein, which comprises using a polycyclic polyoxyalkylene derivative in at least the step of determining the specificity of the target lipid measurement. Is provided.
- the present invention also provides a reagent for measuring lipid in a specific lipoprotein, which comprises a polycyclic polyoxyalkylene derivative acting on a specific lipoprotein and a reagent for measuring a target lipid.
- useful surfactants can be efficiently selected from a large number of surfactants, and using these surfactants, there is no need for pretreatment such as centrifugation, and specific images can be efficiently obtained with simple operations.
- the amount of lipid in the minute can be determined.
- specific measurement is possible with a small number of samples and simple operation, it can be applied to various analytical methods, It is also very useful in the area.
- FIG. 1 is a diagram showing a correlation between the method of the present invention and the conventional method (using Cholestest NHDL).
- FIG. 2 is a diagram showing the correlation between the method of the present invention and the conventional method (using Cholestest LDL).
- FIG. 3 is a diagram showing a correlation between the method of the present invention and a conventional method (Cholestest N HDL is used).
- FIG. 4 is a diagram showing the correlation between the method of the present invention and the conventional method (using Cholestest LDL).
- FIG. 5 is a diagram showing the measurement results of LDL neutral fat according to the method of the present invention.
- FIG. 6 is a diagram showing the measurement results of HDL neutral fat according to the present invention.
- FIG. 7 is a diagram showing a relationship between HLB of the surfactant of the present invention and a correlation coefficient.
- FIG. 8 is a diagram showing the relationship between the number of aryl groups and the correlation coefficient of the surfactant of the present invention.
- Examples of the polycyclic polyoxyalkylene derivative used in the present invention include polycyclic, that is, nonionic or anionic surfactants having two or more aryl groups.
- Examples of the aryl group include a phenyl group, a naphthyl group, an alkylphenyl group, a phenylalkyl group, and a phenylalkenyl group.
- Alkylphenyl groups include C! One C 2. And an alkylphenyl group.
- aryl groups are preferably 2 to 10 and particularly preferably 2 to 8. However, this is not always the case for condensates.
- Preferred examples of the polycyclic group include 1 to 5 aryl groups selected from a phenyl group, a naphthyl group, an alkylphenyl group, a phenylalkyl group and a styryl group on the phenyl group, more preferably 1 to 3 And substituted groups.
- polyoxyalkylene group of the surfactant examples include a polyoxyethylene group, a polyoxyethylene polyoxypropylene group, and a polyoxypropylene group, and a polyoxyethylene group is particularly preferable.
- the number of moles of borooxyalkylene added varies depending on the target lipid to be measured and the type of polyoxyalkylene group, it is preferably 2 to 100, more preferably 5 to 50, particularly preferably 10 to 50.
- the nonionic surfactant is preferably a polyoxyalkylene ether-based nonionic surfactant.
- its HLB is preferably from 12 to 18.
- anionic surfactant a sulfonate ester type, a phosphate ester type or a sulfosuccinate type anionic surfactant is preferable.
- the target lipid is cholesterol
- it is a non-ionic surfactant of HLB 12 to 18 acting on a specific lipoprotein as a polycyclic polyoxyalkylene derivative, and the specificity for the target lipid is It is preferable to use a surfactant which does not depend on the HLB value of the surfactant and is exclusively controlled by the number of aryl groups.
- the target lipid is cholesterol
- it is a nonionic surfactant of HLB 12 to 18 acting on a specific lipoprotein as a polycyclic polyoxyalkylene derivative, and is an interface having two or more aryl groups. It is preferable to use an activator (except for HLB 13 to 15 whose specificity of measurement is affected by the buffer when measuring cholesterol in LDL).
- the target lipid is cholesterol in HDL
- the target lipid is cholesterol in LDL
- polycyclic polyoxyalkylene As derivatives it is preferred to use non-ionic surfactants of HLB 15.1-18, especially HLB 15.3-18, which act preferentially in addition to LDL.
- HLB that acts preferentially besides LDL is 12 to 18 and more than 2 It is preferred to use a nonionic surfactant having an aryl group.
- the polycyclic polyoxyalkylene derivative acts preferentially in addition to LDL Non-ionic with 12 to 15 HLB and 2 or more aryl groups
- a surfactant is used.
- “acting preferentially” means acting preferentially on a specific lipoprotein over other lipoproteins.
- Particularly preferred polyoxyalkylene derivatives include polyoxyalkylene polycyclic phenyl ethers having a plurality of phenyl groups, polyoxyethylene tribenzyl phenyl ether, polyoxyalkylene polystyryl phenyl ether, Polyoxyalkylene phenyl phenol ether, polyoxyalkylene polystyrene phenyl ether condensate, polyoxyalkylene alkyl phenyl ether condensate, polyoxyalkylene distyrenated phenyl ether, polyoxyalkylene styrylated phenyl ether Examples include enyl ether, polyoxyalkylenearylphenyl ether, polyoxyalkylene polycyclic phenylsulfosuccinate, and the like.
- polyoxyalkylene polycyclic polyesters such as Pignol 005 (HLB 14.6, manufactured by Toho Chemical Industry); Newcol 610 (HLB 13.8); Call 710 (HLB 13.6), New Call 7 10F (HLB 13.5), New Call 714 (HLB 15.0), New Call 714F (HLB 14.4), New Call 7 40 ( HLB 17.9), New Coal 2600 FB (HLB 13.4), New Coal 2608 F (HLB 13.0), New Coal 2609 (HLB 13.0) (all manufactured by Nippon Emulsifier); Polyoxyalkylene Polystyryl Fenyle —Tell as Bionin D—61 '12W (HLB 13.0), Pyonin D—6115X (HLB 15.5), Bionin D—6115Z (HLB 15.5) (all manufactured by Takemoto Yushi Co., Ltd.); Poly Oxyalkylenephenylphenol as Solpol T-15 (HLB12.0), Solpol T-20
- Emulgen A-90 as polyoxyalkylene distyrenated phenyl ether (HLB 14.5) (manufactured by Kao Corporation); Sanmol 2 SP-180 as polyoxyalkylene styrylated phenyl ether (HLB 14.5) (Nichika Chemical Co., Ltd.); TSP-16 (HLB 12.7) (Aoki Yushi Co., Ltd.); Polyoxyalkylenearylphenyl ether as Newcalgen FS-12 (HLB 13) (Takemoto Yushi Co., Ltd.); Polyolalkylene polycyclic phenylsulfosuccinate includes Airroll T-1500 (Toho Chemical Industry Co., Ltd.).
- polycyclic polyoxyalkylene derivatives can be used alone, in combination, or in combination with other surfactants.
- the polycyclic polyoxyalkylene derivative of the present invention may be a mixture of a plurality of polycyclic polyoxyalkylene derivatives.
- phenyl ethers having a benzyl group may be in the form of monobenzyl, dibenzyl or tribenzyl alone or in a mixture.
- phenyl ether having a styryl group monostyryl, distyryl, and tristyryl may be used alone or in a mixture.
- the mixing ratio of each form is not particularly limited, however, it is preferable that the mono-form is 1 to 20%, the di-form is 10 to 40%, the tri-form is 40 to 90%, and the mono-form is 2 to 15%,
- the di-isomer is preferably 10 to 40%, and the tri-isomer is preferably 50 to 90%.
- 05 (approximately 7% for the mono-form, 20% for the di-form and 73% for the tri-form).
- the amount of each of these components varies depending on the compound and is not particularly limited, but is 0.0001% by mass to 10% by mass (hereinafter simply referred to as%), preferably 0.001% to 5%. Used in%.
- the polycyclic polyoxyalkylene derivative of the present invention only needs to be in at least the step of determining the specificity of the target lipid measurement.
- the present invention relates to a method and a reagent for measuring a target lipid in a specific lipoprotein, and the specific lipoprotein includes HDL, LDL, IDL, VLDL, chylomicron and a degradation product thereof.
- Target lipids include cholesterol, neutral fats, and phospholipids.
- cholesterol in HDL cholesterol in LDL, cholesterol in VLDL, cholesterol in IDL, cholesterol in chylomicron, cholesterol in these degradation products
- triglyceride in HDL Neutral fat in VLDL, Neutral fat in VLDL, Neutral fat in IDL, Neutral fat in Ilomicron, Neutral fat in these degradation products
- Phospholipid in HDL Phospholipid in LDL, VLDL Phospholipids in IDL, phospholipids in chiromiclone, and phospholipids in these degradation products. Many of these are deeply related to atherosclerotic diseases and need to be separated and quantified.
- the method of the present invention has a step of measuring the target lipid and a step of determining the specificity of the target lipid measurement
- the step of determining the specificity of the target lipid measurement is performed separately from the step of measuring the target lipid. May be performed at the same time. In addition, these steps do not indicate that the reagents and the like are used in stages, but may be used in a system in which these steps are performed.
- the step of determining the specificity of the target lipid measurement includes a step of pretreating a lipoprotein other than the specific lipoprotein, and a step of reacting the target lipid in the target lipoprotein with the measurement enzyme from a pretreated reaction solution. Process and the like.
- a target lipid measurement reagent is used, and the reagent includes an enzyme that releases the target lipid from the lipoprotein, for example, an esterase.
- the specimen body fluids and body components of animals including humans, particularly mammals can be used. However, whole blood, serum, plasma, cerebrospinal fluid, sweat, urine, tears, saliva, skin, mucous membranes, especially serum and plasma are preferred.
- the sample may be diluted as it is or may be separated by a separation device or may be dried.
- the lipoproteins other than the specific lipoprotein are, for example, when the target lipid is a lipid in HDL, lipoproteins other than HDL, that is, LDL, VLDL, IDL, chiromiclone, and their degradation products.
- LDL lipoprotein
- VLDL VLDL
- IDL chiromiclone
- the surfactant of the present invention may have a lower affinity for a specific lipoprotein than another lipoprotein, as opposed to having a high affinity for a specific lipoprotein, and can be used depending on the target lipid.
- the esterase used in the reagent for measuring the target lipid is an enzyme used for measuring the lipid constituting lipoprotein, and may be, for example, an ester bond-degrading enzyme such as cholesterol esterase, lipoprotein lipase, and phospholipid lipase. It does not matter. These may be of microbial origin, animal origin, plant origin, etc., or may be those produced by genetic manipulation. It does not matter whether or not there is chemical modification. These may be in the form of a solution or in a dry state, or may be held or bound to an insoluble carrier.
- an ester bond-degrading enzyme such as cholesterol esterase, lipoprotein lipase, and phospholipid lipase. It does not matter. These may be of microbial origin, animal origin, plant origin, etc., or may be those produced by genetic manipulation. It does not matter whether or not there is chemical modification. These may be in the form of a solution or in a dry state, or may be held or bound to an insoluble carrier.
- enzymes can be used in combination with other enzymes, coenzymes, and color formers for measuring the target lipid, if necessary.
- Other enzymes include cholesterol dehydrogenase, cholesterol oxidase, glycerol phosphatase, glycerol phosphatase, glycerol phosphate dehydrogenase, glycerol dehydrogenase, pyruvate phosphatase, lactate dehydrogenase, Choline oxidase, alkaline phosphatase, peroxidase, catalase, diaphorase, etc. are used. These may be of microbial origin, animal origin, plant origin, etc., or may be those produced by genetic manipulation.
- Cotinamide adenine dinucleotide (NAD), nicotinamide adenine dinucleotide reduced form (NADH), nicotinamide adenine dinucleotide phosphate
- NAD Cotinamide adenine dinucleotide
- NADH nicotinamide adenine dinucleotide reduced form
- NAD P Nicotinamide adenine dinucleotide reduced phosphate
- thio NAD thio NADP
- any coloring agent that forms a pigment by the action of P ⁇ D ⁇ diaphorase may be used.
- 4-aminoantipyrine a single dye of dye, and a formazan dye can be used.
- These enzymes can be used alone or in combination of two or more. The amount used varies depending on the enzyme and is not particularly limited, but is 0.001 unit to 100 units ZmL And preferably 0.1 unit to 100 units. The two steps in the present invention may be performed individually or in the same reagent.
- the reagents containing enzymes in the present invention include other enzymes and salts, buffers for pH adjustment, surfactants, preservatives, and albumin for the purpose of adjusting the action of the enzymes without impairing the specificity of the measurement.
- Reagents having affinity for specific lipoproteins, salts of azide as preservatives and inhibitors of lipase can also be added.
- polyadiones or salts of divalent metals are components that control the reaction of the target lipid measurement reagent, and are used in combination with a polycyclic polyoxyalkylene derivative that is a surfactant that acts on a specific lipoprotein. Is also good.
- Buffers such as Good's buffer, phosphoric acid, tris, phthalic acid, and citrate, as well as any buffer that can be generally used in the pH range of 5 to 9 and any that have a buffering action in this range can be used. it can.
- the amount of use is not particularly limited, it is preferably 0.05 M to 2 M, particularly preferably 0.01 M to 1 M.
- the reactivity of the polycyclic polyoxyalkylene derivative used in the present invention does not depend on the buffer.
- the reaction temperature may be the same or different in the two steps, and is preferably a temperature at which the reagent of the present invention is in a solution state, for example, 10 to 40 ° C.
- the surfactant used in combination with the polycyclic polyoxyalkylene derivative is, for example, the target lipid is measured after the lipid in the lipoprotein other than the target is already pretreated by the polycyclic polyoxyalkylene derivative. And those that regulate the reaction of the target lipid measurement reagent by adjusting the action of the enzyme without impairing the specificity of the measurement. These do not require specificity as in the polycyclic polyoxyalkylene derivative used in the step of determining specificity.
- these surfactants a surfactant having no aryl group and a surfactant having only one aryl group can be used.
- Non-ionic or ionic and non-ionic polyoxyethylene alkyl ethers without aryl groups, polyoxyethylene polyoxypropylene condensates, and one phenyl group
- Polyoxydylene alkylphenyl ethers having the following formulas can be used.
- Polyoxyethylene alkyl ethers such as Emulgen 709 (manufactured by Kao Corporation) and polyoxyethylene alkylphenyl ethers such as Triton XI 00 (manufactured by Sigma) such as polyoxyethylene polyoxy propylene condensate
- Pull Mouth Nick F-108 made by Asahi Denka Co., Ltd.
- Bile acids can be used as the ionicity.
- the method for finally detecting the target lipid is not particularly limited.
- an absorbance analysis performed by further combining a oxidase with oxidase or diaphorase, a coenzyme Alternatively, a method of directly detecting hydrogen or hydrogen peroxide, a method of measuring the oxidation and reduction of a metal or the like, and the like can be used.
- the reagent of the present invention can be provided not only in a solution state but also in a dry state or a gel state.
- Each formulation is applied to glass bottles, plastic containers, various insoluble carriers such as latex, glass, colloid particles and spherical carriers, semiconductor and glass flat plates, paper and nitrocellulose membrane carriers, and fibrous carriers. It can be provided in various forms, such as impregnation.
- HDL or LDL cholesterol in the measurement of HDL or LDL cholesterol in the present invention, for example, cholesterol oxidase and cholesterol oxidase are used in the presence of a polycyclic polyalkylene derivative.
- the sterol esterase is reacted.
- Cholesterol in lipoproteins other than HDL or LDL is pretreated in the presence of a polycyclic polyoxyalkylene derivative, and cholesterol oxidase and cholesterol are added to HDL or LDL remaining in the next step. Esterase may be reacted.
- free glycerol is pretreated in the first step, lipoprotein lipase is reacted in the next step, and the reaction is measured by reacting with a general triglyceride measuring reagent.
- the polycyclic polyoxyalkylene derivative may be used in the first step or in the second step.
- the system comprises a step of pre-treating free glycerol so as not to participate in the reaction and a step of allowing lipoprotein lipase to act on a specific lipoprotein.
- Method for measuring neutral fat in specific lipoprotein by reacting lipoprotein lipase with neutral fat in specific lipoprotein in the presence of polycyclic polyoxyalkylene derivative; and pretreatment so that free glycerol does not participate in the reaction And the step of allowing lipoprotein lipase to act on the specific lipoprotein in the measurement of triglyceride in the specific lipoprotein, in the presence of the polycyclic polyoxyalkylene derivative of HLB 12 to 15
- a method for measuring triglycerides in specific lipoproteins by pretreating triglycerides other than glycerol and specific lipoproteins may be mentioned.
- the step of pre-treating free glycerol may be performed when the free glycerol in the sample is separately measured or when the glycerol in the sample is negligible compared to the neutral fat in the specific lipoprotein. May be omitted, or the reagents may be omitted.
- the present invention will be further described with reference to examples, but the present invention is not limited thereto.
- the polycyclic polyoxyalkylene derivative may be referred to as the surfactant of the present invention.
- HDL cholesterol was measured with a Hitachi 7170 type automatic analyzer, and the measured value was compared with the measured value of a commercially available HD L cholesterol measuring reagent.
- Fifteen human sera were used as samples.
- the reagent of the present invention is prepared by adding 240 L of a reagent containing 0.01% 4-aminoantipyrine, lO OmM PIPES buffer (pH 6.5) to 2.4 L of serum, and then 37 minutes at 37 ° C.
- the surfactant of the present invention 1%, 1 unit / mL cholesterol oxidase (Oriental yeast), 1 unit ZmL cholesterol esterase (Asahi Kasei), 1 unit / mL peroxidase, 0.04% N, N— 80 L of a reagent containing disulfobutyl metatoluidine and lO OmM PI PES buffer (pH 6.5) was added, and the absorbance change at a sub wavelength of 700 nm / main wavelength of 60 Onm was measured at 37 ° C.
- HDL cholesterol was measured with a Hitachi 7170 type automatic analyzer, and the measured value was compared with the measured value of a commercially available HD L cholesterol measuring reagent.
- the reagent of the present invention was prepared by adding 240 L of a reagent containing 0.014 aminoaminopyrine, 45 M digitonin (Tokyo Kasei) and 100 mM PI PES buffer (pH 6.5) to 2.4 L of serum, After warming for 5 minutes, the surfactant of the present invention 1%, 1 unit / mL cholesterol oxidase (Oriental yeast), 1 unit ZmL cholesterol esterase (Asahi Kasei), 1 unit ZmL peroxidase, 0 Add 80 L of a reagent containing 04% by weight N, N-disulfobutyl metatoluidine, lOOmM PI PES buffer (pH 6.5) and change the absorbance at a
- HDL cholesterol was measured with a Hitachi 7170 type automatic analyzer, and the measured value was compared with the measured value of a commercially available HD L cholesterol measuring reagent. Fifteen human sera were used as samples.
- the reagent of the present invention contains 0.
- LDL cholesterol was measured by a Hitachi 7170 type automatic analyzer, and the measured value was compared with the measured value of a commercially available LDL cholesterol measuring reagent. Fifteen human sera were used as samples.
- the reagent of the present invention contains 1 unit mL cholesterol oxidase (Toyobo), 1 unit / mL cholesterol esterase (Asahi Kasei), 1 unit / mL peroxidase, and 0.02% in 2.4 L of serum.
- HDL cholesterol was measured with a Hitachi 7170 type automatic analyzer, and the measured value was compared with the measured value of a commercially available HD L cholesterol measuring reagent. Fifty serum samples were used as samples.
- the reagent of the present invention was prepared by adding 1 unit Z mL cholesterol oxidase (Toyobo), 1 unit ZmL peroxidase, 0.02% N, N-disulfobutyl methyl toluidine, 0.2 mM flufenam Add 240 L of reagent containing acid (Sigma), 50 mM NaCl, 5 OmM Bis_Tris buffer (pH 6), heat at 37 ° C for 5 minutes, then 1 unit ZmL cholesterol esterase (Asahi Kasei) Add 80 L of reagent containing 1% phenol 005, 0.02% 4-aminoantipyrine, 5 OmM Bis—T 1-is buffer (pH6), sub wavelength 700 nm at 37 ° C Z main wavelength 600
- LDL cholesterol is automatically analyzed using a Hitachi 7170 type automatic analyzer.
- the measured value was compared with the measured value of a commercially available LDL cholesterol measuring reagent. Fifty serum samples were used as samples.
- the reagent of the present invention contains 1 unit / mL cholesterol oxidase (Asahi Kasei), 1 unit / mL cholesterol esterase (Asahi Kasei), 1% PGNOL 005 (Toho Chemical Industry), 1 unit ZmL , 0.01% 4-Aminoantipyrine, 20 OmM NaC 5 OmM MES buffer (pH 6.5)
- First reagent 2 40 ⁇ iL was added, and after heating at 37 ° C for 5 minutes, 0.04% Add 80 zL of a reagent containing N, N-disulfobutyl metatoluidine, 1% Emulgen 709, and 5 OmM MES buffer (pH 6.5).
- the surfactant of the present invention has properties that can be used for measuring lipids in a plurality of specific lipoproteins.
- HDL cholesterol was measured with a Hitachi 7170 type automatic analyzer, and the measured value was compared with the measured value of a commercially available HD L cholesterol measuring reagent.
- 20 human sera were used as samples.
- the reagent of the present invention is prepared by adding 240 L of a reagent containing 0.01% 4-aminoaminopyrine and 10 OmM PIPES buffer (pH 6.5) to 2.4 L of serum and adding the mixture at 37 ° C for 5 minutes.
- Figure 3 shows the results.
- LDL cholesterol was measured with a Hitachi 7170 automatic analyzer, and the measured value was compared with the measured value of a commercially available LDL cholesterol measuring reagent. 20 human sera were used as samples.
- the reagent of the present invention contains 1 unit ZmL cholesterol oxidase (Toyobo), 1 unit / mL cholesterol esterase (Asahi Kasei), 1 unit ZmL oxidase, 0.02% N, N in 2.4 zL of serum.
- the surfactant of the present invention has properties that can be used for measuring lipids in a plurality of specific lipids.
- LDL cholesterol reagents of the method of the present invention were prepared using various buffers, and the measured values were compared. The measurement was performed using a Hitachi 7-70 automatic analyzer and 15 human serum samples were used.
- the reagent of the present invention contains 1 unit / mL cholesterol oxidase (Toyobo), 1 unit / mL cholesterol esterase (Asahi Kasei), 1 unit ZmL peroxidase, 0.02% N, N— Disulfo Add 240 / zL of the first reagent consisting of various buffer solutions containing 10 OmM butylmetolidine and 1% phenol 005.After heating at 37 for 5 minutes, 0.02% 4-aminoantipyrine, 1% Emulgen 709, 80 ⁇ L of a reagent containing 100 mM of various buffers was added, and the absorbance change at a sub wavelength of 660 nm / main wavelength of 546 nm was measured at 37 ° C.
- Serum was used as a sample to separate each lipoprotein fraction by ultracentrifugation, and the total cholesterol in each fraction was measured and plotted in FIG.
- the neutral fat of the same sample was measured by the method of the present invention and plotted in FIG. The measurement was performed using a Hitachi 7150 type automatic analyzer, and the total cholesterol was measured using Pure Auto ST-CHO (Daiichi Pure Chemicals).
- the reagent for measuring LDL triglyceride of the present invention comprises: 0.5 unit in 3 L of serum; ZmL glycerol kinase (Asahi Kasei); 3 units; ZmL glycerose triphosphate oxidase (Toyobo); 1.5 units; ZmL peroxidase (Toyobo), 1 unit / mL LPL (Toyobo), 1% Egnol 005 (Toho Chemical Industry), 3 mM magnesium chloride, 0.5 mM calcium chloride, 2.5 mM ATP, 0.02% ethylsulfobutyl meta Add 300 L of the first reagent consisting of toluidine and 5 OmM 3 buffer (16.3), heat at 37 ° C for 5 minutes, and add 0.011% Reagent 100 containing monoaminoantipyrine, 1% Emulgen 709, and 5 OmM MES buffer (pH 6.3) was added, and the change in absorbance at
- Serum was used as a sample to separate each lipoprotein fraction by ultracentrifugation, and the total neutral fat in each fraction was measured and plotted in FIG.
- the neutral fat of the same sample was measured by the method of the present invention and plotted in FIG. Measurements were performed using a Hitachi 7170 automatic analyzer, and Pure Neutral STG-N (Daiichi Pure Chemicals) was used for total neutrality measurement.
- the HDL triglyceride measuring reagent of the present invention comprises 3 units in serum 2.81 7111 glycerol kinase (Asahi Kasei), 3 units ZmL glycerose triphosphate oxidase (Toyobo), 500 units / 1111 ⁇ catalase, Add 210 L of the first reagent consisting of 3 mM magnesium chloride, 3 mM ATP, 2 mM ethylsulfobutylmeta toluidine, and 10 OmM PI PES buffer (pH 7) .
- 50 omt L Lipase (Asahi Kasei)
- 1 unit / mL monoglyceride lipase Asahi Kasei
- 10 units ZmL peroxidase Toyobo
- Equinol 005 Toho Chemical
- 0.04% 4-aminoantipyrine 70 L of a
- the HLB value has no particular significance, but is preferably 12 or more.
- FIG. 7 shows the relationship between the relative numbers shown in Examples 1 to 4 of the present invention and the HLB of the surfactant of the present invention. Figure 7 shows that there is no certain tendency in the relationship between the HLB value and the correlation coefficient of the surfactant of the present invention. I have.
- FIG. 8 shows the relationship between the correlation coefficients shown in Examples 1 to 4 of the present invention and the number of aryl groups of the surfactant of the present invention. Condensate-based surfactants of the present invention are excluded. FIG. 8 shows that when the number of aryl groups in the surfactant is 2 or more, a better correlation coefficient can be obtained than in the single control method. In the present invention, when counting aryl groups, the number of phenyl groups is represented as a representative of those having a benzene ring which is a common structural feature.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA05005708A MXPA05005708A (es) | 2002-11-27 | 2003-11-26 | Metodo para medir lipido en lipoproteina especifica. |
CA002507725A CA2507725A1 (en) | 2002-11-27 | 2003-11-26 | Method of measuring lipid in specific lipoprotein |
US10/536,186 US7682831B2 (en) | 2002-11-27 | 2003-11-26 | Method of measuring lipid in specific lipoprotein |
JP2004555044A JPWO2004048605A1 (ja) | 2002-11-27 | 2003-11-26 | 特定リポ蛋白中の脂質測定法 |
EP03775898A EP1580279A4 (en) | 2002-11-27 | 2003-11-26 | METHOD OF MEASURING LIPID INSPECIFIC LIPOPROTEIN |
AU2003284453A AU2003284453A1 (en) | 2002-11-27 | 2003-11-26 | Method of measuring lipid in specific lipoprotein |
AU2010200171A AU2010200171A1 (en) | 2002-11-27 | 2010-01-15 | Method of measuring lipid in specific lipoprotein |
US12/696,903 US20100136591A1 (en) | 2002-11-27 | 2010-01-29 | Method of measuring lipid in specific lipoprotein |
US12/982,133 US20110091917A1 (en) | 2002-11-27 | 2010-12-30 | Method of measuring lipid in specific lipoprotein |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-343979 | 2002-11-27 | ||
JP2002343979 | 2002-11-27 | ||
JP2002346115 | 2002-11-28 | ||
JP2002-346115 | 2002-11-28 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/696,903 Division US20100136591A1 (en) | 2002-11-27 | 2010-01-29 | Method of measuring lipid in specific lipoprotein |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004048605A1 true WO2004048605A1 (ja) | 2004-06-10 |
Family
ID=32396276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/015080 WO2004048605A1 (ja) | 2002-11-27 | 2003-11-26 | 特定リポ蛋白中の脂質測定法 |
Country Status (8)
Country | Link |
---|---|
US (3) | US7682831B2 (ja) |
EP (2) | EP1580279A4 (ja) |
JP (2) | JPWO2004048605A1 (ja) |
KR (1) | KR101216051B1 (ja) |
AU (2) | AU2003284453A1 (ja) |
CA (1) | CA2507725A1 (ja) |
MX (1) | MXPA05005708A (ja) |
WO (1) | WO2004048605A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100443884C (zh) * | 2005-06-29 | 2008-12-17 | 中生北控生物科技股份有限公司 | 低密度脂蛋白胆固醇的定量测定方法、试剂及试剂盒 |
EP2065708A1 (en) | 2007-11-28 | 2009-06-03 | Fujifilm Corporation | Method for measuring high-density lipoprotein cholesterol |
WO2011136316A1 (ja) * | 2010-04-30 | 2011-11-03 | 協和メデックス株式会社 | 低密度リポ蛋白中のコレステロールの測定方法、測定用試薬及び測定用キット |
WO2012057333A1 (ja) * | 2010-10-29 | 2012-05-03 | アークレイ株式会社 | 低密度リポタンパク質中のコレステロールの測定方法及び測定用キット |
US8685663B2 (en) | 2008-11-14 | 2014-04-01 | Kyowa Medex Co., Ltd. | Method, reagent and kit for measuring cholesterol in low-density lipoproteins |
WO2015030236A1 (ja) | 2013-08-30 | 2015-03-05 | 積水メディカル株式会社 | 高比重リポ蛋白中のコレステロール測定方法および該方法に用いる試薬 |
WO2015076284A1 (ja) * | 2013-11-21 | 2015-05-28 | 協和メデックス株式会社 | 血清又は血漿中の高密度リポ蛋白の安定化剤及び安定化方法 |
JPWO2013157642A1 (ja) * | 2012-04-20 | 2015-12-21 | デンカ生研株式会社 | 低密度リポ蛋白以外のリポ蛋白中のトリグリセリドの消去方法 |
JP7436981B2 (ja) | 2020-02-21 | 2024-02-22 | 国立研究開発法人産業技術総合研究所 | コレステロールエステラーゼ活性が向上したポリペプチド |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05005708A (es) * | 2002-11-27 | 2005-07-26 | Daiichi Pure Chemicals Co Ltd | Metodo para medir lipido en lipoproteina especifica. |
GB0609494D0 (en) * | 2006-05-12 | 2006-06-21 | Oxford Biosensors Ltd | HDL cholesterol sensor using specific surfactant |
GB0609493D0 (en) * | 2006-05-12 | 2006-06-21 | Oxford Biosensors Ltd | Cholesterol sensor |
US20090203054A1 (en) * | 2006-05-12 | 2009-08-13 | Lindy Murphy | HDL Cholesterol Sensor Using Selective Surfactant |
EP2116613B1 (en) * | 2007-09-05 | 2016-11-02 | ARKRAY, Inc. | Method and test piece for measuring low density lipoprotein (ldl) cholesterol |
JP6182008B2 (ja) | 2013-07-24 | 2017-08-16 | デンカ生研株式会社 | 高密度リポタンパク質3中のコレステロールの定量方法及び定量試薬 |
CN105353142B (zh) * | 2015-12-07 | 2017-05-10 | 郑州兰森生物技术有限公司 | 一种稳定性强的血清总胆固醇检测单试剂 |
JP6829009B2 (ja) * | 2016-05-24 | 2021-02-10 | デンカ株式会社 | トリグリセリドリッチリポ蛋白中のコレステロールの定量方法及び定量試薬 |
CN107449748B (zh) * | 2017-08-10 | 2020-08-28 | 东软威特曼生物科技(南京)有限公司 | 高密度脂蛋白胆固醇检测试剂盒及其使用方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997045553A1 (en) * | 1996-05-29 | 1997-12-04 | Daiichi Pure Chemicals Co., Ltd. | Method for quantitatively determining ldl cholesterols |
WO1999010526A1 (fr) * | 1997-08-27 | 1999-03-04 | Daiichi Pure Chemicals Co., Ltd. | Methodes de quantification de cholesterol des lipoproteines de haute densite |
JPH11318496A (ja) * | 1996-04-15 | 1999-11-24 | Denka Seiken Co Ltd | 低密度リポ蛋白中のコレステロ―ルの定量方法 |
WO2002038800A1 (fr) * | 2000-11-08 | 2002-05-16 | Arkray, Inc. | Dispositif de test permettant de doser le cholesterol hdl (lipoproteine a haute densite) |
JP2002214239A (ja) * | 2000-11-14 | 2002-07-31 | Dai Ichi Pure Chem Co Ltd | 脂質測定方法およびそれに用いる試薬 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2061282B (en) | 1979-10-22 | 1983-03-30 | Symphar Sa | Method for the clinical separation of a-and lipoproteins and kit for carrying out this method |
JPS5991897A (ja) * | 1982-11-19 | 1984-05-26 | Nippon Chemiphar Co Ltd | リポ蛋白質中リン脂質分画濃度の測定方法 |
DE3636851A1 (de) * | 1986-10-29 | 1988-05-11 | Boehringer Mannheim Gmbh | Verfahren und reagenz zur spezifischen bestimmung des cholesterins der hdl-fraktion |
JP3107474B2 (ja) | 1993-02-17 | 2000-11-06 | 国際試薬株式会社 | リポ蛋白分画中の成分の定量方法 |
JP2600065B2 (ja) | 1994-03-08 | 1997-04-16 | 協和メデックス株式会社 | 高密度リポ蛋白中のコレステロールの定量法 |
JP2653755B2 (ja) | 1994-03-08 | 1997-09-17 | 協和メデックス株式会社 | 高密度リポ蛋白中のコレステロールの定量法 |
DE4424274C1 (de) | 1994-07-09 | 1996-01-11 | Jenoptik Technologie Gmbh | Einrichtung zur Manipulation eines Synchrotronstrahlenbündels |
JPH0828734A (ja) | 1994-07-21 | 1996-02-02 | Yamatake Honeywell Co Ltd | 電空変換器 |
JP3256241B2 (ja) | 1995-03-16 | 2002-02-12 | 協和メデックス株式会社 | 低密度リポ蛋白中のコレステロールの定量法 |
EP0764848A4 (en) | 1995-03-20 | 2001-04-11 | Kyowa Medex Co Ltd | METHOD FOR QUANTIFYING CHOLESTEROL IN LOW DENSITY OR VERY LOW DENSITY LIPOPROTEIN |
JP3866308B2 (ja) | 1995-05-26 | 2007-01-10 | 第一化学薬品株式会社 | 中性脂肪測定試薬 |
JP3614514B2 (ja) | 1995-06-21 | 2005-01-26 | 国際試薬株式会社 | 高比重リポ蛋白分画中のコレステロールの定量方法及び定量用試薬キット |
JP3446486B2 (ja) | 1995-07-21 | 2003-09-16 | 和光純薬工業株式会社 | リポタンパク中の成分の測定法 |
JP3058602B2 (ja) | 1996-04-15 | 2000-07-04 | デンカ生研株式会社 | 低密度リポ蛋白中のコレステロールの定量方法 |
JP3288033B2 (ja) | 1996-12-09 | 2002-06-04 | デンカ生研株式会社 | 高密度リポ蛋白中のコレステロール定量用試薬 |
DE69734194T2 (de) | 1996-12-09 | 2006-06-29 | Denka Seiken Co., Ltd. | Verfahren zur bestimmung des cholesteringehalts von high-density-lipoproteinen |
DE69737108T2 (de) | 1997-04-14 | 2007-07-05 | Denka Seiken Co., Ltd. | Methode zur quantifizierung von cholesterol in lipoproteinen geringer dichte |
US5814472A (en) | 1997-05-13 | 1998-09-29 | Wako Pure Chemical Industries, Ltd. | Measurement of LDL-cholesterol |
WO1998059068A1 (fr) | 1997-06-25 | 1998-12-30 | International Reagents Corporation | Procede servant a analyser des specimens biologiques afin de rechercher des substances contenues dans leurs constituants et reactif utilise dans ce procede |
DE19756255C2 (de) | 1997-12-17 | 1999-11-11 | Heinrich Wieland | Verfahren und Diagnostikprodukt zur Bestimmung von in Lipoprotein enthaltenem Triglycerid |
JP2000116400A (ja) | 1998-10-09 | 2000-04-25 | Ttk Kenkyusho:Kk | リポ蛋白中のコレステロールの定量法 |
ATE387505T1 (de) | 1999-01-20 | 2008-03-15 | Kyowa Medex Co Ltd | Verfahren zum quantifizieren von triglyzeriden im lipoprotein |
DE60039418D1 (de) * | 1999-03-01 | 2008-08-21 | Sysmex Corp | Verfahren zum austesten biologischer probenkomponenten |
WO2000060112A1 (fr) | 1999-04-01 | 2000-10-12 | Masahiko Okada | Procede de quantification de triglycerides contenus dans des lipoproteines a tres faible densite et dans des lipoproteines a densite moyenne |
ATE330026T1 (de) * | 1999-06-21 | 2006-07-15 | Daiichi Pure Chemicals Co Ltd | Verfahren zum vorbehandeln von proben und zum quantifizieren von cholesterin in spezifischen lipoproteinen |
JP4456715B2 (ja) * | 2000-02-28 | 2010-04-28 | 協和メデックス株式会社 | レムナント様リポ蛋白中のコレステロールの測定方法および測定試薬 |
WO2002040707A1 (fr) * | 2000-11-14 | 2002-05-23 | Daiichi Pure Chemicals Co., Ltd. | Procede de mesure des lipides et reactif associe |
DE60330264D1 (de) | 2002-10-16 | 2010-01-07 | Kyowa Medex Co Ltd | Verfahren und reagens zur messung von cholesterin in lipoproteinen hoher dichte |
MXPA05005708A (es) * | 2002-11-27 | 2005-07-26 | Daiichi Pure Chemicals Co Ltd | Metodo para medir lipido en lipoproteina especifica. |
US20050032141A1 (en) | 2003-07-17 | 2005-02-10 | Dimagno Theodore John | Dry analytical element for high-density lipoprotein cholesterol quantification |
US20050037504A1 (en) | 2003-07-17 | 2005-02-17 | Dimagno Theodore John | One-step assay for high-density lipoprotein cholesterol |
US7662831B2 (en) * | 2006-07-27 | 2010-02-16 | Wyeth Llc | Tetracyclic indoles as potassium channel modulators |
-
2003
- 2003-11-26 MX MXPA05005708A patent/MXPA05005708A/es unknown
- 2003-11-26 CA CA002507725A patent/CA2507725A1/en not_active Abandoned
- 2003-11-26 AU AU2003284453A patent/AU2003284453A1/en not_active Abandoned
- 2003-11-26 WO PCT/JP2003/015080 patent/WO2004048605A1/ja active Application Filing
- 2003-11-26 JP JP2004555044A patent/JPWO2004048605A1/ja active Pending
- 2003-11-26 EP EP03775898A patent/EP1580279A4/en not_active Withdrawn
- 2003-11-26 EP EP10002306A patent/EP2194142A1/en not_active Withdrawn
- 2003-11-26 KR KR1020057009374A patent/KR101216051B1/ko active IP Right Grant
- 2003-11-26 US US10/536,186 patent/US7682831B2/en not_active Expired - Fee Related
-
2009
- 2009-08-31 JP JP2009199895A patent/JP2009282044A/ja active Pending
-
2010
- 2010-01-15 AU AU2010200171A patent/AU2010200171A1/en not_active Abandoned
- 2010-01-29 US US12/696,903 patent/US20100136591A1/en not_active Abandoned
- 2010-12-30 US US12/982,133 patent/US20110091917A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11318496A (ja) * | 1996-04-15 | 1999-11-24 | Denka Seiken Co Ltd | 低密度リポ蛋白中のコレステロ―ルの定量方法 |
WO1997045553A1 (en) * | 1996-05-29 | 1997-12-04 | Daiichi Pure Chemicals Co., Ltd. | Method for quantitatively determining ldl cholesterols |
WO1999010526A1 (fr) * | 1997-08-27 | 1999-03-04 | Daiichi Pure Chemicals Co., Ltd. | Methodes de quantification de cholesterol des lipoproteines de haute densite |
WO2002038800A1 (fr) * | 2000-11-08 | 2002-05-16 | Arkray, Inc. | Dispositif de test permettant de doser le cholesterol hdl (lipoproteine a haute densite) |
JP2002214239A (ja) * | 2000-11-14 | 2002-07-31 | Dai Ichi Pure Chem Co Ltd | 脂質測定方法およびそれに用いる試薬 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100443884C (zh) * | 2005-06-29 | 2008-12-17 | 中生北控生物科技股份有限公司 | 低密度脂蛋白胆固醇的定量测定方法、试剂及试剂盒 |
EP2065708A1 (en) | 2007-11-28 | 2009-06-03 | Fujifilm Corporation | Method for measuring high-density lipoprotein cholesterol |
US8685663B2 (en) | 2008-11-14 | 2014-04-01 | Kyowa Medex Co., Ltd. | Method, reagent and kit for measuring cholesterol in low-density lipoproteins |
WO2011136316A1 (ja) * | 2010-04-30 | 2011-11-03 | 協和メデックス株式会社 | 低密度リポ蛋白中のコレステロールの測定方法、測定用試薬及び測定用キット |
JPWO2011136316A1 (ja) * | 2010-04-30 | 2013-07-22 | 協和メデックス株式会社 | 低密度リポ蛋白中のコレステロールの測定方法、測定用試薬及び測定用キット |
JP5832995B2 (ja) * | 2010-04-30 | 2015-12-16 | 協和メデックス株式会社 | 低密度リポ蛋白中のコレステロールの測定方法、測定用試薬及び測定用キット |
WO2012057333A1 (ja) * | 2010-10-29 | 2012-05-03 | アークレイ株式会社 | 低密度リポタンパク質中のコレステロールの測定方法及び測定用キット |
JP5728490B2 (ja) * | 2010-10-29 | 2015-06-03 | アークレイ株式会社 | 低密度リポタンパク質中のコレステロールの測定方法及び測定用キット |
JPWO2013157642A1 (ja) * | 2012-04-20 | 2015-12-21 | デンカ生研株式会社 | 低密度リポ蛋白以外のリポ蛋白中のトリグリセリドの消去方法 |
WO2015030236A1 (ja) | 2013-08-30 | 2015-03-05 | 積水メディカル株式会社 | 高比重リポ蛋白中のコレステロール測定方法および該方法に用いる試薬 |
WO2015076284A1 (ja) * | 2013-11-21 | 2015-05-28 | 協和メデックス株式会社 | 血清又は血漿中の高密度リポ蛋白の安定化剤及び安定化方法 |
JP7436981B2 (ja) | 2020-02-21 | 2024-02-22 | 国立研究開発法人産業技術総合研究所 | コレステロールエステラーゼ活性が向上したポリペプチド |
Also Published As
Publication number | Publication date |
---|---|
JPWO2004048605A1 (ja) | 2006-03-23 |
US20060014207A1 (en) | 2006-01-19 |
KR101216051B1 (ko) | 2012-12-27 |
MXPA05005708A (es) | 2005-07-26 |
AU2003284453A1 (en) | 2004-06-18 |
KR20050086781A (ko) | 2005-08-30 |
AU2010200171A1 (en) | 2010-02-04 |
EP1580279A4 (en) | 2007-06-13 |
US20110091917A1 (en) | 2011-04-21 |
US7682831B2 (en) | 2010-03-23 |
EP2194142A1 (en) | 2010-06-09 |
EP1580279A1 (en) | 2005-09-28 |
JP2009282044A (ja) | 2009-12-03 |
CA2507725A1 (en) | 2004-06-10 |
US20100136591A1 (en) | 2010-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009282044A (ja) | 特定リポ蛋白中の脂質測定法 | |
US4892815A (en) | Process and reagent for the specific determination of the cholesterol of the HDL fraction | |
KR101394802B1 (ko) | 소립자 저비중 리포 단백의 정량 시약 | |
US8785146B2 (en) | Method for quantitative measurements of HDL-C and LDL-C | |
JP5243484B2 (ja) | コレステロール定量用試料の前処理方法およびこれを利用する特定のリポ蛋白中のコレステロール定量法 | |
JPH08201393A (ja) | コレステロールの定量方法 | |
EP1132482B1 (en) | Method and reagent for determination of cholesterol in remnant-like lipoprotein particles | |
WO2001094619A1 (fr) | Methode d'analyse de composants dans des echantillons biologiques | |
JP4542234B2 (ja) | コレステロール定量用試料の前処理方法およびこれを利用する特定のリポ蛋白中のコレステロール定量法 | |
WO2000057191A1 (fr) | Procede de quantification du cholesterol | |
CN100408691C (zh) | 特定脂蛋白中的脂质测定法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004555044 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2006014207 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003775898 Country of ref document: EP Ref document number: 10536186 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057009374 Country of ref document: KR Ref document number: 2003284453 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/005708 Country of ref document: MX Ref document number: 2507725 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A91953 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057009374 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003775898 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10536186 Country of ref document: US |